Posts

BMS receives FDA approval for Opdivo to treat NSCLC

Oct 6, 2024

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Admin...

Resilience secures funds to enhance production of essen...

Oct 6, 2024

National Resilience’s subsidiary Resilience Government Services has received aro...

A rational design approach to RNA targeting could repla...

Oct 6, 2024

At ELRIG 2024, Dr. Maria Duca described how her lab’s rational design approach b...

Editas trades part of Vertex CRISPR therapy licencing r...

Oct 6, 2024

WuXi debates sale of pharma operations as BIOSECURE Act...

Oct 6, 2024

WuXi is considering the sale of some US and European operations to mitigate the ...

The benefits of using a nimble platform from phase to p...

Oct 6, 2024

It is common for sponsors to switch digital platforms between clinical trial pha...

FDA lifts clinical hold on Avidity’s lead antibody conj...

Oct 6, 2024

Two years after the FDA placed partial clinical hold, Avidity can resume researc...

NHS proposes phased launch for Eli Lilly’s Mounjaro

Oct 6, 2024

The roadmap suggests those with the greatest clinical need will get priority acc...

Recordati to acquire worldwide rights to Sanofi’s antib...

Oct 6, 2024

Recordati has reached an agreement with Sanofi for acquiring the worldwide right...

Can You Lose Weight With Vitamin B12?

Oct 5, 2024

You may have heard of people losing weight by getting vitamin B12 shots or takin...

Gilead signs agreements to facilitate access to HIV pre...

Oct 4, 2024

Gilead Sciences has announced the signing of voluntary licencing agreements with...

Eli Lilly to invest $4.5bn for drug manufacturing and t...

Oct 4, 2024

Eli Lilly has announced a $4.5bn investment to establish the Lilly Medicine Foun...

Social media algorithms are driving the GLP-1 drugs boom

Oct 4, 2024

GLP-1 RAs are being recommended on social media, raising questions about who can...

ImmunoPrecise and Biotheus partner on bispecific antibo...

Oct 4, 2024

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology co...

Novaliq and Laboratoires Théa announce EC approval for ...

Oct 4, 2024

Novaliq and Laboratoires Théa have announced approval from the European Commissi...

A rational design approach to RNA-targeting to target l...

Oct 4, 2024

At ELRIG 2024, Dr. Maria Duca described how her lab’s rational design approach b...